Plasma Fractionation Market Size, Share & Trends Analysis Report By Product (Albumin, Immunoglobulins), By Method (Centrifugation, Depth Filtration), By Application, By End-use, By Region,- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The global plasma fractionation market size was exhibited at USD 30.50 billion in 2023 and is projected to hit around USD 70.89 billion by 2033, growing at a CAGR of 8.8% during the forecast period 2024 to 2033.

Key Takeaways:

• North America dominated the regional market with a share of 55.0% in 2023.
• The immunoglobulins segment is anticipated to witness a significant growth rate of 8.9% from 2024 to 2033.
• The neurology segment dominated the global market with a revenue of USD 8,356.9 in 2023.
• The centrifugation segment captured the highest share of 38.0% in 2023,
• The hospitals & clinics segment captured the highest revenue share in 2023,

Plasma Fractionation Market Report Scope

The major driver of the market's expansion is the growing prevalence of elderly people around the globe, who are more susceptible to rare disorders that call for the usage of blood derivatives. Additionally, the increased use of immunoglobulins & alpha-1-antitrypsin in various fields of medicine around the world is anticipated to drive market growth. Another important element driving the expansion of this market is the rise in blood collection facilities worldwide.

The increased government funding and corporate involvement in research and development activities for plasma treatments are also anticipated to boost market growth. In addition, the COVID-19 pandemic has provided numerous chances for biotechnology and biopharma firms to participate in R&D projects involving plasma treatments. A lot of businesses have started working together to research how well fractionation therapy works for COVID-19 patients. For instance, in March 2020, the Food and Drug Administration (FDA) and the Biomedical Advanced Research Development Authority (BARDA) joined forces with Grifols, a biopharma business focused on producing medicines made from plasma, to develop treatments for COVID-19.

Despite the destructive effects of the new coronavirus pandemic on some businesses, the global industry has been observed to have grown significantly over the past several years. More people were adversely impacted by the viral infection with serious problems as the COVID-19 pandemic neared its worst stage, which prompted plasma as a treatment. However, the cost of this therapy is anticipated to rise as a result of increased government support and corporate involvement in research and development, impeding the market growth. Moreover, plasma therapy gave patients reason for optimism because COVID-19 patients were effectively treated using fractionation therapy. For instance, in July 2020, the Hindu reported that patients with COVID-19 in Chennai's Rajiv Gandhi Government General Hospital had made a full recovery through plasma therapy.

Growing R&D activities, awareness programs encouraging blood donation, and investments from major players are projected to create profitable revenue opportunities for industry participants in the global market. Moreover, the market is also being driven ahead by supportive government initiatives to increase awareness of the use of plasma-derived products. For instance, in March 2023, the WHO Model List of essential medicines includes several plasma-derived medicinal products (PDMPs), identifying them as drugs thought to be the most efficient and secure for addressing the most essential requirements in a health system and providing guidelines on increased supply of PDMPs in low & middle-income countries.

Increased investments by major players in the production of advanced & effective treatments are likely to support market growth throughout the projected timeframe. For instance, in April 2020, To create a viable plasma-derived medication for treating COVID-19, CSL Behring & Takeda Pharmaceutical Company Ltd. partnered with Biotest, BPL, LFB, and Octapharma. The collaboration will get started right away with the research and development of a single, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin drug that has the potential to help people with major COVID-19 problems. Such initiatives by companies are likely to supplement the market growth in the coming years.

Segments Insights:

Product Insights

The immunoglobulins segment is anticipated to witness a significant growth rate of 8.9% from 2022 to 2030. Immunoglobulin is becoming more extensively used for the administration, cure, and identification of metabolic disorders globally, which is one of the most significant aspects influencing the industry's expansion. As a result, immunoglobulin's extensive use will also increase its supremacy and enhance market opportunities.

Additionally, the market for coagulation factors is expanding as a result of factors like the approval of new medications, the high frequency of bleeding diseases, and growing initiatives & donation for people with severe bleeding disorders like hemophilia. For instance, in April 2019, under a long-term initiative to support people with hemophilia, Grifols International SA, a supplier of plasma-derived therapeutics, provided blood clotting factor medications (100 million international units) for the treatment of hemophilic patients.

Application Insights

The neurology segment dominated the global market with a revenue of USD 8,356.9 in 2023. The global rise in the prevalence of neurological disorders is a major driver of market expansion. For instance, the Centers for Disease Control and Prevention estimates that over 795,000 Americans get a stroke each year. Additionally, the growing elderly population raises the risks of neurovascular illnesses such as stroke becoming more prevalent. Additionally, after the age of 55, the risk of having a stroke doubles, which encourages the use of plasma-based products for the treatment and supports market expansion.

On the other hand, the oncology segment exhibits the fastest rate during the projected period. The range of plasma therapies for cancer is quickly growing to address challenging targets that were previously incurable, including those with the possibility of metastasis and drug resistance. Furthermore, a comprehensive investigation of the multifaceted impact of cold atmospheric plasma in cancer treatment is required to get toward widespread clinical implementation of the drug, which contributes to the segment's growth.

Method Insights

The centrifugation segment captured the highest share of 38.0% in 2023, as well as the fastest growth rate throughout the forecast period. Centrifugation is an essential step in getting high-quality blood supernatant. Additionally, it aids researchers in consistent blood separation and better clinical outcomes for patients. Thus, the increasing demand for centrifugation instruments would supplement the market growth.

The utilization of industrial-scale chromatographic fractionation as well as purification techniques for plasma fractionation has increased recently. A new generation of therapeutic plasma products, particularly coagulation factors, protease inhibitors, and anticoagulants, have been developed. As a result, chromatography has made it possible to create new therapeutic items for treating patients who have acquired or congenital impairments in plasma protein levels. Thus, it will drive market growth.

End-Use Insights

The hospitals & clinics segment captured the highest revenue share in 2023, as well as the fastest growth rate throughout the forecast period. Due to the increased off-label use of plasma fractionation products in hospitals to treat a variety of diseases, improved infrastructure & healthcare services offered by hospitals, the segment is anticipated to witness significant growth. Furthermore, the complex disorders that can be treated in modern clinical settings have a significant demand for plasma fractionation products.

Moreover, the growing number of surgical procedures and the increasing use of plasma-derived products drive the market growth. As per the NCBI, a total of 13 million surgical procedures were conducted in the US between January 1, 2019, and January 30, 2023. Such factors are also expected to fuel market growth.

Regional Insights

North America dominated the regional market with a share of 55.0% in 2023. This is a result of increased awareness and numerous advantages of plasma among North American citizens and an increase in the occurrence of respiratory disorders. Additionally, the presence of significant players, an increase in the number of plasma collection facilities, a rise in the consumption of immunoglobulin, and the ability to supply plasma owing to the viability of plasma collections & distribution all support the expansion of the regional market.

The plasma fractionation market in the Asia Pacific is expanding due to an increase in public and private funding for research and development, favorable government regulations,increased use of immunoglobulins, and rising prevalence of target diseases with an aging population with blood-related diseases, and rising plasma-based treatment adoption.

Some of the prominent players in the Plasma fractionation market include:

• Grifols S.A.
• CSL Limited
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Kedrion S.p.A
• LFB S.A.
• Biotest AG
• Sanquin
• Bio Products Laboratory Ltd.
• Intas Pharmaceuticals Ltd

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2023 to 2033. For this study, Nova one advisor, Inc. has segmented the global plasma fractionation market.

Product Scope

• Albumin
• Immunoglobulins

• • Intravenous immunoglobulins
  • Subcutaneous immunoglobulins
  • Others

• Coagulation Factors

• • Factor VIII
  • Factor IX
  • Von Willebrand Factor
  • Prothrombin Complex Concentrates
  • Fibrinogen Concentrates
  • Others

• Protease Inhibitors
• Others

Method Scope

• Centrifugation
• Depth Filtration
• Chromatography
• Others

Application Scope

• Neurology
• Hematology
• Oncology
• Immunology
• Pulmonology
• Others

End Use Scope

• Hospitals & Clinics
• Clinical Research
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)